Toggle navigation EN

Publikationen 2006

  1. Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M and Geisslinger G. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006 79(1):35-48
  2. Lötsch J, Skarke C, Wieting J, Oertel B, Schmidt H, Brockmöller J and Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006 79(1): 72-89
  3. Klinkhardt U, Wenzel E,Harder S. The Retention Index Test Homburg (RTH-II): Response to clopidogrel and comparison with aggregometry and CD62p-expression. Platelets 2006 Feb 1;17(1):42-48
  4. Lötsch J and Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 2006 Jan 17; [Epub ahead of print]
  5. Burian M, Neumann T, Weber M, Brandt R, Geisslinger G, Mitrovic M, Hamm C. Nickel release, a possible indicator for duration of antiplatelet treatment, from a nickel cardiac device in vivo: a study in patients with atrial septal deffects implanted with an amplatzer occluder. In J Clin Pharmacol Ther 2006;44(3): 107-112
  6. Loibl S, von Minckwitz G, Gwyn K, Ellis P, Blohmer JU, Schlegelberger B, Keller M, Harder S, Theriault RL, Crivellari D, Klingebiel T, Louwen F, Kaufmann M. Breast carcinoma during pregnancy. Cancer. 2006 Jan 15;106(2):237-46
  7. Lötsch J and Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006 Feb 9; [Epub ahead of print]
  8. Rohrbacher M, Kirchhof A, Skarke C, Geisslinger G and Lötsch J. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing. Pharmacogenomics 2006 Mar;7(2):167-76
  9. Lötsch J and Hummel T. The clinical significance of electrophysiological measures of olfactory function. Behav Brain Res 2006 Mar 22; [Epub ahead of print]
  10. Bette M, Nüsing RM, Mutters R, Zamora ZB, Menendez S, Schulz S. Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum. Shock. 2006 Jan;25(1):23-29.
  11. Wang H, Ehnert C, Brenner GJ, Woolf CJ : Bradykinin and peripheral sensitization. Minireview Biol Chem 2006; 387: 11-14
  12. Niederberger E, Manderscheid C and Geisslinger G. Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochem Biophys Res Commun 2006 April; 342 (3):940-948
  13. Graff S, Harder S.  Argatroban. Dtsch Med Wschr 2006;131:676-678
  14. Brenneis B, Maier T, Schmidt R, Hofacker A, Zulauf L, Jakobsson PJ, Scholich K, and Geisslinger G. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclo-oxygenase 1 inhibition FASEB J 2006 Jul;20(9):1352-60
  15. Oertel BG, Schmidt R, Schneider A, Geisslinger G, and Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenetics 2006 Sept (in press)
  16. Tegeder I and Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol. 2006 Apr;373(1):1-17
  17. Schaible HG, Schmelz M and Tegeder I. Pathophysiology and treatment of pain in joint disease. Adv. Drug Del. Rev. 2006. May 20;58(2):323-42
  18. Lötsch J and Geisslinger G. Misestimating the role of an active metabolite when modeling the effects after administration of the parent compound only. Clin Pharmacol Ther 2006 Jul;80(1):95-7
  19. Grösch S, Maier TJ, Schiffmann S, and Geisslinger G. COX-2-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006 Jun 7;98(11):736-47
  20. Michelson G, Wärntges S, Leidig S, Lötsch J, and Geisslinger G. Nimodipine Plasma Concentration and Retinal Blood Flow in Healthy Subjects. Investigative Ophthalmology & Visual Science. 2006 Aug;47(8):3479-86
  21. von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S and Haberl A. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy Br J Clin Pharm 2006 Nov;62(5):552-9
  22. von Hentig N, Mueller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski  S and Harder S. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. Eur J Med Res (2006) Jun 30;11(6):236-44
  23. Frohberg P, Drutkowski G, Wobst I. Monitoring eicosanoid biosynthesis via lipoxygenase and cyclooxygenase pathways in human whole blood by single HPLC run. J Pharm Biomed Analysis 2006 (in press)
  24. Schmidt R, Bremerich DH, and Geisslinger G. High sensitive determination of sufentanil in human plasma of parturients and neonates following patient-controlled epidural analgesia (PCEA). J Chromatogr B 2006 May 19;836(1-2):98-107
  25. Koster A, Buz S, Hetzer R , Kuppe H, Breddin HK, Harder S. Anticoagulation with Argatroban in Patients with HIT-anibodies After Cardiovascular Surgery With Cardiopulmonary Bypass: First Results of The ARG-E-03 Trial. J Thor Cardiovascular Surg 2006 Sep;132(3):699-700
  26. Scholich K, Geisslinger G. Is mPGES-1 a promising target for pain therapy?  Trends in Pharmacological Sciences, August 2006 (in press)
  27. Weigert A, Johann AM, von Knethen A, Schmidt H, Geisslinger G, and Brüne B. Apoptotic cells promote macrophage survival by releasing the anti-apoptotic mediator sphingosine-1-phosphate Blood, May 2006; doi:10.1182/blood-2006-04-014852
  28. Janssen A, Maier TJ, Schiffmann S, Coste O, Seegel M, Geisslinger G and Grösch S. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- and R-ibuprofen treatment. Eur J Pharmacol 2006 Jul 1;540(1-3):24-33
  29. Niederberger E, Schmidtko A, Coste O, Marian C, Ehnert C, andGeisslinger G. The glutamate transporter GLAST is involved in spinal nociceptive processing. Biochem Biophys Res Commun Jul 28;346(2):393-9
  30. Gudziol V, Lötsch J, Hähner A, Zahnert T, and Hummel T. Clinical significance of results from olfactory testing. Laryngoscope Sep 25; [Epub ahead of print]
  31. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2006 Jul 4; [Epub ahead of print]
  32. Theilig F, Debiec H, Nafz B, Ronco P, Nusing RM, Seyberth HW, Pavenstadt H, Bouby N, Bachmann S. Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertensive rats. Am. J. Physiol. Renal Physiol. 2006, Jun 20 (Epub)
  33. Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G and Lötsch J. The cyclooxygenase-2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 2006; Dec;80(6):621-32
  34. Brochhausen C, Neuland P, Kirkpatrick CJ, Nusing RM, Klaus G. Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthitis Res. Ther. 2006;8(3):R78. Epub 2006 Apr 28.
  35. Weber AA, Hohlfeld Th, Harder S: Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antipyretic drugs? Arguments against. Thromb Haemost 2006 Oct;96(4):413-6
  36. Schmidt H, Schmidt R, Geisslinger G. LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. Prostaglandins Other Lipid Mediat 2006; 81:162-70
  37. Lötsch J, Dudziak R, Freynhagen R, Marschner J, and Geisslinger G. Fatal respiratory depression after multiple intravenous morphine injections. Clinical Pharmacokinetics 2006; 45(11):1051-60
  38. Lötsch J, Stuck B and Hummel T. The human mu-opioid receptor gene polymorphism 118A>G decreases cortical activation in response to specific nociceptive stimulation. Behavioral Neuroscience 2006 (accepted)
  39. Rohrbacher M, Kirchhof A, Geisslinger G and Lötsch J. Pyrosequencing™ based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics 2006 Oct;7(7):995-1002.
  40. Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H, Ehnert C, Nejim J, Marian C, Scholz J, Wu T, Allchorne A, Diatchenko L, Binshtok AM, Goldman D, Adolph J, Sama S, Atlas SJ, Carlezon WA, Parsegian A,Lötsch J, Fillingim RB, Maixner W, Geisslinger G, Max MB and Woolf CJ.  GTP-cyclohydrolase, the rate-limiting enzyme in tetrahydrobiopterin biosynthesis, regulates pain sensitivity and persistence. Nat Med 2006 Oct 22; [Epub ahead of print]
  41. von Hentig N, Koenigs C, Elanjikal S, Linde R, Dunsch D, Kreuz W, Funk MB. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006. 11(9) 377-80
  42. Michaelis M, Michaelis R, Suhan T, Schmidt H, Mohamed A, Doerr HW and Cinatl Jr. J. Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion. FASEB 2006 (in press)
  43. Müssig K, Knaus-Dittmann D, Schmidt H, Mörike K and Häring HU. Secondary adrenal failure and secondary amenorrhea following hydromorphone treatment. Clin Endocrinol (letter) 2006 (accepted)